Passa al contenuto
Merck

Melanoblast transcriptome analysis reveals pathways promoting melanoma metastasis.

Nature communications (2020-01-18)
Kerrie L Marie, Antonella Sassano, Howard H Yang, Aleksandra M Michalowski, Helen T Michael, Theresa Guo, Yien Che Tsai, Allan M Weissman, Maxwell P Lee, Lisa M Jenkins, M Raza Zaidi, Eva Pérez-Guijarro, Chi-Ping Day, Kris Ylaya, Stephen M Hewitt, Nimit L Patel, Heinz Arnheiter, Sean Davis, Paul S Meltzer, Glenn Merlino, Pravin J Mishra
ABSTRACT

Cutaneous malignant melanoma is an aggressive cancer of melanocytes with a strong propensity to metastasize. We posit that melanoma cells acquire metastatic capability by adopting an embryonic-like phenotype, and that a lineage approach would uncover metastatic melanoma biology. Using a genetically engineered mouse model to generate a rich melanoblast transcriptome dataset, we identify melanoblast-specific genes whose expression contribute to metastatic competence and derive a 43-gene signature that predicts patient survival. We identify a melanoblast gene, KDELR3, whose loss impairs experimental metastasis. In contrast, KDELR1 deficiency enhances metastasis, providing the first example of different disease etiologies within the KDELR-family of retrograde transporters. We show that KDELR3 regulates the metastasis suppressor, KAI1, and report an interaction with the E3 ubiquitin-protein ligase gp78, a regulator of KAI1 degradation. Our work demonstrates that the melanoblast transcriptome can be mined to uncover targetable pathways for melanoma therapy.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Anti-vinculina monoclonale, clone hVIN-1, ascites fluid
Sigma-Aldrich
Z-Leu-Leu-Leu-al, ≥90% (HPLC)
Sigma-Aldrich
MISSION® esiRNA, targeting human KDELR3
Sigma-Aldrich
MISSION® esiRNA, targeting human KDELR1
Sigma-Aldrich
MISSION® esiRNA, targeting human AMFR